topSkip to main content

Menu, Secondary

Menu Trigger

Menu

Research Administration & Regulation

AAU joined a coalition of 98 other organizations in sending a letter to the incoming Biden-Harris administration on rescinding the human fetal tissue (HFT) research restrictions. 
AAU has prepared key recommendations for the Biden-Harris Administration to help preserve the government-university partnership.
AAU has crafted a document for our members to use and share broadly that includes our recommendations for the upcoming “Phase Four” COVID-19 relief and stimulus legislation.
AAU shared key policy recommendations with candidates at the first presidential debate hosted by Case Western Reserve University and the Cleveland Clinic.
This is a document detailing the phase four COVID-19 relief and stimulus proposals and legislative provisions.
This document summarizes the originally introduced and updated House HEROES Act (H.R. 6800.)
Government investment in the infrastructure that facilitates scientific research and advancement helped make America safer, stronger, and more successful in the 20th century. The challenges of the 21st century make it more important than ever to renew our commitment to that kind of forward-thinking investment.
AAU joined EDUCAUSE, COGR, and APLU in sending a letter expressing concern for the DOD and the CMMC Accreditation Body urging DOD to exclude fundamental research from the CMMC program and establish a dialogue with member institutions.  
The letter urges the board to consider the importance of human fetal tissue research to develop new tests, treatments, and cures to “reduce suffering from human diseases” during their evaluation of the ethics of research proposals using human fetal tissue
This memorandum to federal policymakers represents a compilation of responses received from AAU Senior Research Officers concerning the need to extend regulatory flexibilities granted to federal research agencies and to universities by the Office of Management in Budget in response to issues arising for the conduct of research resulting from COVID-19.